Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 244, Issue 11, 2006, Pages 1491-1496

  Uusitalo, Hannu ^a   Kähönen, Mika ^b   Ropo, Auli ^c   Mäenpää, Jukka ^c   Bjärnhall, Gunilla ^d   Hedenström, Hans ^d   Turjanmaa, Väinö ^e  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c Santen Oy   (Finland)

^d UPPSALA UNIVERSITY   (Sweden)

^e PIRKANMAA HOSPITAL DISTRICT   (Finland)

Author keywords

Exercise; Heart rate; Timolol

Indexed keywords

TIMOLOL; TIMOLOL MALEATE; TIMOSAN;

ADULT; AQUEOUS SOLUTION; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EXERCISE; FEMALE; GLAUCOMA; HEAD TILTING; HEART RATE; HUMAN; HYDROGEL; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; RISK BENEFIT ANALYSIS; SPIROMETRY;

EID: 33751010170     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-006-0328-0     Document Type: Article

References (15)

1. Boger WP III (1979) Timolol: Short term "escape" and long term "drift". Ann Ophthalmol 11:1239-1242
2. Brooks AM, Gillies WE (1992) Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging 2:208-221
3. Dickstein K, Aarsland T (1996) Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Am J Ophthalmol 121:367-371
4. Dickstein K, Hapnes R, Aarsland T (2001) Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. Am J Ophthalmol 132:626-631
5. Everitt DE, Avorn J (1990) Systemic effects of medications used to treat glaucoma. Ann Int Med 112:120-125
6. Frishman WH, Kowalski M, Nagnur S, Warshafsky S, Sica D (2001) Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: Focus on beta-adrenergic blockade. Heart Dis 3:386-397
7. Hayreh SS, Podhajsky P, Zimmerman MB (1999) Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol 128:301-309
8. Heel RC, Brodgen RN, Speight TM, Avery GS (1979) Timolol: A review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs 17:38-55
9. Mayer H, von der Ohe N (1996) Efficacy of a novel hydrogel formulation in human volunteers. Ophthalmologica 210:101-103
10. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN (1985) Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 102:606-611
11. Niño J, Tahvanainen K, Uusitalo H, Turjanmaa V, Hutri-Köhönen N, Kaila T, Ropo A, Kuusela T, Kähönen M (2002) Cardiovascular effects of ophthalmic 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Clin Physiol Funct Imaging 22:271-278
12. Rouland JF, Morel-Mandrino P, Elena PP, Polzer H, Sunder Raj P (2002) Timolol 0.1% gel (Nyogel 0.1%) once daily versus conventional timolol 0.5% solution twice daily: A comparison of efficacy and safety. Ophthalmologica 216:449-454
13. Silverstone D, Zimmerman T, Choplin N, Mundorf T, Rose A, Stoecker J, Kelley E, Lue J (1991) Evaluation of once-daily levobunolol 0.25% and timolol 0.25% therapy for increased intraocular pressure. Am J Ophthalmol 112:56-60
14. Thylefors B, Négrel AD, Pararajasegaram R, Dadzie KY (1995) Global data on blindness. Bull World Health Organ 73:115-121
15. Uusitalo H, Niño J, Tahvanainen K, Turjanmaa V, Ropo A, Tuominen J, Kähönen M (2005) Efficacy and systemic side effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta Ophthalmol Scand 83:723-728